View in EDS

Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.

Saved in:
Bibliographic Details
Title: Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.
Authors: Yee AJ; Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA., Laubach JP; Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA., Campagnaro EL; Division of Hematology and Oncology, University of Michigan Cancer Center, Ann Arbor, MI., Lipe BC; Department of Hematology/Oncology, University of Rochester, Rochester, NY., Nadeem O; Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA., Friedman RS; Newton-Wellesley Hospital, Newton, MA., Cole CE; Division of Hematology and Oncology, University of Michigan Cancer Center, Ann Arbor, MI., O'Donnell EK; Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA., Bianchi G; Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA., Branagan AR; Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA., Schlossman RL; Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA., Shapiro SJ; Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA., Harrington CC; Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA., Burke JN; Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA., Gammon MT; Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA., Lively KJ; Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA., Reimonn CA; Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA., Andrade DX; Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA., Redd R; Dana-Farber Cancer Institute, Boston, MA., Lohr JG; Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA., Anderson KC; Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA., Richardson PG; Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA., Raje NS; Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA.
Source: Blood advances [Blood Adv] 2025 Mar 11; Vol. 9 (5), pp. 1163-1170.
Publication Type: Journal Article; Clinical Trial, Phase II; Multicenter Study
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39626297
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Yee+AJ%22">Yee AJ</searchLink>; Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Laubach+JP%22">Laubach JP</searchLink>; Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Campagnaro+EL%22">Campagnaro EL</searchLink>; Division of Hematology and Oncology, University of Michigan Cancer Center, Ann Arbor, MI.<br /><searchLink fieldCode="AU" term="%22Lipe+BC%22">Lipe BC</searchLink>; Department of Hematology/Oncology, University of Rochester, Rochester, NY.<br /><searchLink fieldCode="AU" term="%22Nadeem+O%22">Nadeem O</searchLink>; Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Friedman+RS%22">Friedman RS</searchLink>; Newton-Wellesley Hospital, Newton, MA.<br /><searchLink fieldCode="AU" term="%22Cole+CE%22">Cole CE</searchLink>; Division of Hematology and Oncology, University of Michigan Cancer Center, Ann Arbor, MI.<br /><searchLink fieldCode="AU" term="%22O'Donnell+EK%22">O'Donnell EK</searchLink>; Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Bianchi+G%22">Bianchi G</searchLink>; Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Branagan+AR%22">Branagan AR</searchLink>; Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Schlossman+RL%22">Schlossman RL</searchLink>; Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Shapiro+SJ%22">Shapiro SJ</searchLink>; Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Harrington+CC%22">Harrington CC</searchLink>; Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Burke+JN%22">Burke JN</searchLink>; Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Gammon+MT%22">Gammon MT</searchLink>; Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Lively+KJ%22">Lively KJ</searchLink>; Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Reimonn+CA%22">Reimonn CA</searchLink>; Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Andrade+DX%22">Andrade DX</searchLink>; Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Redd+R%22">Redd R</searchLink>; Dana-Farber Cancer Institute, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Lohr+JG%22">Lohr JG</searchLink>; Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Anderson+KC%22">Anderson KC</searchLink>; Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Richardson+PG%22">Richardson PG</searchLink>; Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Raje+NS%22">Raje NS</searchLink>; Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101698425%22">Blood advances</searchLink> [Blood Adv] 2025 Mar 11; Vol. 9 (5), pp. 1163-1170.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase II; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+of+Hematology%22">American Society of Hematology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101698425 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2473-9537 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2224739529%22">24739529 </searchLink><i>NLM ISO Abbreviation: </i>Blood Adv <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39626297
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1182/bloodadvances.2024014717
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1163
    Titles:
      – TitleFull: Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Yee AJ
      – PersonEntity:
          Name:
            NameFull: Laubach JP
      – PersonEntity:
          Name:
            NameFull: Campagnaro EL
      – PersonEntity:
          Name:
            NameFull: Lipe BC
      – PersonEntity:
          Name:
            NameFull: Nadeem O
      – PersonEntity:
          Name:
            NameFull: Friedman RS
      – PersonEntity:
          Name:
            NameFull: Cole CE
      – PersonEntity:
          Name:
            NameFull: O'Donnell EK
      – PersonEntity:
          Name:
            NameFull: Bianchi G
      – PersonEntity:
          Name:
            NameFull: Branagan AR
      – PersonEntity:
          Name:
            NameFull: Schlossman RL
      – PersonEntity:
          Name:
            NameFull: Shapiro SJ
      – PersonEntity:
          Name:
            NameFull: Harrington CC
      – PersonEntity:
          Name:
            NameFull: Burke JN
      – PersonEntity:
          Name:
            NameFull: Gammon MT
      – PersonEntity:
          Name:
            NameFull: Lively KJ
      – PersonEntity:
          Name:
            NameFull: Reimonn CA
      – PersonEntity:
          Name:
            NameFull: Andrade DX
      – PersonEntity:
          Name:
            NameFull: Redd R
      – PersonEntity:
          Name:
            NameFull: Lohr JG
      – PersonEntity:
          Name:
            NameFull: Anderson KC
      – PersonEntity:
          Name:
            NameFull: Richardson PG
      – PersonEntity:
          Name:
            NameFull: Raje NS
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 11
              M: 03
              Text: 2025 Mar 11
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2473-9537
          Numbering:
            – Type: volume
              Value: 9
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: Blood advances
              Type: main
ResultId 1